2026 Dengue hemorrhagic fever indication strategy covering epidemiology, NS5 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 West Nile neuroinvasive disease indication strategy covering epidemiology, NS5 biology, active trials, transactions, unmet need, competition and market…

2026 Rift Valley fever indication strategy covering epidemiology, Viral polymerase biology, active trials, transactions, unmet need, competition and market…

2026 Chikungunya fever indication strategy covering epidemiology, nsP2 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Oropouche fever indication strategy covering epidemiology, Viral polymerase biology, active trials, transactions, unmet need, competition and market…

2026 Severe fever with thrombocytopenia syndrome indication strategy covering epidemiology, Viral polymerase biology, active trials, transactions, unmet need,…

2026 Progressive multifocal leukoencephalopathy indication strategy covering epidemiology, VP1 biology, active trials, transactions, unmet need, competition and…

2026 Parainfluenza virus infection indication strategy covering epidemiology, HN protein biology, active trials, transactions, unmet need, competition and market…

2026 Epstein-Barr virus post-transplant lymphoproliferative disease indication strategy covering epidemiology, EBNA1 biology, active trials, transactions, unmet…

2026 Adenovirus infection in transplant recipients indication strategy covering epidemiology, DNA polymerase biology, active trials, transactions, unmet need,…

2026 Echinococcosis indication strategy covering epidemiology, Beta-tubulin biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 BK polyomavirus nephropathy indication strategy covering epidemiology, VP1 biology, active trials, transactions, unmet need, competition and market…